<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320827</url>
  </required_header>
  <id_info>
    <org_study_id>CS1008-A-U101</org_study_id>
    <nct_id>NCT00320827</nct_id>
  </id_info>
  <brief_title>Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)</brief_title>
  <official_title>Phase 1 Study of CS-1008, a Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), Administered Weekly to Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the
      recommended Phase 2 dose and the maximum tolerated dose. Drug will be administered for six
      weeks and possibly up to 12 weeks depending on response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the recommended Phase 2 dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacokinetics of CS-1008 administered weekly</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the immunogenicity of CS-1008 by monitoring for anti-CS-1008 antibodies</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study potential biomarkers of CS-1008 activity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To make preliminary assessments of anti-tumor effects of CS-1008</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Malignancies</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-1008 (humanized anti-DR5 antibody)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically diagnosed metastatic solid tumors or lymphomas (with
             no leukemic component) which are refractory to, not curable with, or not eligible for
             standard treatment(s).

          -  Eighteen years of age or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status equal to or less than 2

          -  Resolution of any toxic effects (except alopecia) of prior therapy to National Cancer
             Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 grade of
             equal to or less than 1

          -  Men and women of childbearing potential must be willing to consent to use effective
             contraception while on treatment and for at least 3 months thereafter.

          -  All female patients of childbearing potential must have a negative pregnancy test
             (serum or urine) within 3 days prior to treatment

          -  Patients must be fully informed about their illness and the investigational nature of
             the study protocol

        Exclusion Criteria:

          -  Anticipation of the need for a major surgical procedure or radiation therapy during
             the study

          -  Treatment with chemotherapy, hormonal therapy, radiotherapy, major surgery, or any
             investigational agent within 4 weeks (6 weeks for nitrosoureas, mitomycin C,
             immunotherapy, biological therapy, or major surgery) of study enrollment

          -  Cumulative radiation therapy to greater than 25% of the total bone marrow

          -  Any of the following within 6 months prior to study enrollment: myocardial infarction,
             severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York
             Heart Association (NYHA) class III or IV congestive heart failure, cerebrovascular
             accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or
             other clinically significant thromboembolytic event; clinically significant pulmonary
             disease (e.g., severe chronic obstructive pulmonary disease [COPD] or asthma)

          -  Patients with a clinically active brain metastasis (i.e., not treated or still
             requiring therapy with steroids or radiotherapy [RT]; or with progression 4 weeks
             after the completion of RT) or an uncontrolled seizure disorder, spinal cord
             compression, or carcinomatous meningitis

          -  Clinically significant active infection which requires antibiotic therapy, or
             HIV-positive patients receiving antiretroviral therapy.

          -  Chronic diarrhea, inflammatory bowel disease, or partial bowel obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2006</study_first_submitted>
  <study_first_submitted_qc>April 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <last_update_submitted>September 10, 2007</last_update_submitted>
  <last_update_submitted_qc>September 10, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2007</last_update_posted>
  <keyword>Apoptosis</keyword>
  <keyword>Death receptor 5</keyword>
  <keyword>Cancer</keyword>
  <keyword>Advanced solid malignancies and lymphomas (without leukemic component)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

